EXTRAMEDULLARY HEMATOPOIESIS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (TDT): A SYSTEMATIC REVIEW

Objective: Thalassemia is one of the most common hemoglobinopathies, with around 5% of the world's population expected to have some degree and type of thalassemia. Beta thalassemia (BT) occurs due to a deficient production of the beta-globin chain of hemoglobin. Extramedullary hematopoiesis (EM...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eihab Subahi, Fateen Ata, Phool Iqbal, Mousa AlHiyari, Mohamed Yassin, Hassan Choudry, Ashraf Soliman, Vincenzo De Sanctis
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/57437c422e69460d84aa52c0d02b6516
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:57437c422e69460d84aa52c0d02b6516
record_format	dspace
spelling	oai:doaj.org-article:57437c422e69460d84aa52c0d02b65162021-11-10T04:37:36ZEXTRAMEDULLARY HEMATOPOIESIS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (TDT): A SYSTEMATIC REVIEW2531-137910.1016/j.htct.2021.10.1058https://doaj.org/article/57437c422e69460d84aa52c0d02b65162021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921012050https://doaj.org/toc/2531-1379Objective: Thalassemia is one of the most common hemoglobinopathies, with around 5% of the world's population expected to have some degree and type of thalassemia. Beta thalassemia (BT) occurs due to a deficient production of the beta-globin chain of hemoglobin. Extramedullary hematopoiesis (EMH) is one of the complications of BT, mainly observed in minor/intermedia subtypes. EMH is the production of blood cells outside the marrow as a compensatory response to longstanding hypoxia. Due to chronic transfusions, it is not expected in patients with beta-thalassemia major (BTM). However, there are increasingly reported cases of EMH in BTM. The incidence of EMH in BTM is thought to be <1%. However, it seems that the true incidence is much higher than expected. This review aims to pool the available data and provide cumulative evidence on the occurrence of EMH in BTM patients. Methodology: We aim to conduct a systematic review via searching multiple electronic databases (PubMed, Scopus, Google Scholar) to identify eligible articles from any date up to December 2020. Eligible studies should report extramedullary hematopoiesis in beta-thalassemia major. Case reports, case series, observational studies with cross-sectional or prospective research design, case-control studies, and experimental studies will be included if found relevant. Two reviewers (FA and ES) will individually analyze the study quality using the statistical methodology and categories guided by the Cochrane Collaboration Handbook, PRISMA guidelines, and Joanna Briggs Institute checklist for case reports and series. Results: Data from 253 cases of EMH in BTM patients were extracted with mean age of 35.3 +/- 0.5 years. Mean hemoglobin at presentation with EMH was 8.2 +/- 2.1 mg/dL. Lower limb weakness was the most common presenting feature (N=23) (paraspinal EMH). Magnetic resonance imaging (MRI) was the most widely used diagnostic modality (N=226). Overall, blood transfusion was the commonest reported treatment (N=30), followed by radiotherapy (N=20), surgery (N=15), hydroxyurea (N=12), steroids (N=6), and exchange transfusion (N=2). An outcome was reported in 20% of patients, all recovered, with no reported mortality. Conclusion: EMH is considered a rare phenomenon in BTM patients. It can occur in any organ system with varied clinical features. MRI can effectively diagnose EMH, and conservative management has similar results compared to invasive treatments. Larger studies, focusing on outcomes may enhance guidelines on preventive and therapeutic strategies for managing EMH in BTM.Eihab SubahiFateen AtaPhool IqbalMousa AlHiyariMohamed YassinHassan ChoudryAshraf SolimanVincenzo De SanctisElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S50-S51 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Eihab Subahi Fateen Ata Phool Iqbal Mousa AlHiyari Mohamed Yassin Hassan Choudry Ashraf Soliman Vincenzo De Sanctis EXTRAMEDULLARY HEMATOPOIESIS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (TDT): A SYSTEMATIC REVIEW
description	Objective: Thalassemia is one of the most common hemoglobinopathies, with around 5% of the world's population expected to have some degree and type of thalassemia. Beta thalassemia (BT) occurs due to a deficient production of the beta-globin chain of hemoglobin. Extramedullary hematopoiesis (EMH) is one of the complications of BT, mainly observed in minor/intermedia subtypes. EMH is the production of blood cells outside the marrow as a compensatory response to longstanding hypoxia. Due to chronic transfusions, it is not expected in patients with beta-thalassemia major (BTM). However, there are increasingly reported cases of EMH in BTM. The incidence of EMH in BTM is thought to be <1%. However, it seems that the true incidence is much higher than expected. This review aims to pool the available data and provide cumulative evidence on the occurrence of EMH in BTM patients. Methodology: We aim to conduct a systematic review via searching multiple electronic databases (PubMed, Scopus, Google Scholar) to identify eligible articles from any date up to December 2020. Eligible studies should report extramedullary hematopoiesis in beta-thalassemia major. Case reports, case series, observational studies with cross-sectional or prospective research design, case-control studies, and experimental studies will be included if found relevant. Two reviewers (FA and ES) will individually analyze the study quality using the statistical methodology and categories guided by the Cochrane Collaboration Handbook, PRISMA guidelines, and Joanna Briggs Institute checklist for case reports and series. Results: Data from 253 cases of EMH in BTM patients were extracted with mean age of 35.3 +/- 0.5 years. Mean hemoglobin at presentation with EMH was 8.2 +/- 2.1 mg/dL. Lower limb weakness was the most common presenting feature (N=23) (paraspinal EMH). Magnetic resonance imaging (MRI) was the most widely used diagnostic modality (N=226). Overall, blood transfusion was the commonest reported treatment (N=30), followed by radiotherapy (N=20), surgery (N=15), hydroxyurea (N=12), steroids (N=6), and exchange transfusion (N=2). An outcome was reported in 20% of patients, all recovered, with no reported mortality. Conclusion: EMH is considered a rare phenomenon in BTM patients. It can occur in any organ system with varied clinical features. MRI can effectively diagnose EMH, and conservative management has similar results compared to invasive treatments. Larger studies, focusing on outcomes may enhance guidelines on preventive and therapeutic strategies for managing EMH in BTM.
format	article
author	Eihab Subahi Fateen Ata Phool Iqbal Mousa AlHiyari Mohamed Yassin Hassan Choudry Ashraf Soliman Vincenzo De Sanctis
author_facet	Eihab Subahi Fateen Ata Phool Iqbal Mousa AlHiyari Mohamed Yassin Hassan Choudry Ashraf Soliman Vincenzo De Sanctis
author_sort	Eihab Subahi
title	EXTRAMEDULLARY HEMATOPOIESIS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (TDT): A SYSTEMATIC REVIEW
title_short	EXTRAMEDULLARY HEMATOPOIESIS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (TDT): A SYSTEMATIC REVIEW
title_full	EXTRAMEDULLARY HEMATOPOIESIS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (TDT): A SYSTEMATIC REVIEW
title_fullStr	EXTRAMEDULLARY HEMATOPOIESIS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (TDT): A SYSTEMATIC REVIEW
title_full_unstemmed	EXTRAMEDULLARY HEMATOPOIESIS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (TDT): A SYSTEMATIC REVIEW
title_sort	extramedullary hematopoiesis in patients with transfusion dependent β-thalassemia (tdt): a systematic review
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/57437c422e69460d84aa52c0d02b6516
work_keys_str_mv	AT eihabsubahi extramedullaryhematopoiesisinpatientswithtransfusiondependentbthalassemiatdtasystematicreview AT fateenata extramedullaryhematopoiesisinpatientswithtransfusiondependentbthalassemiatdtasystematicreview AT phooliqbal extramedullaryhematopoiesisinpatientswithtransfusiondependentbthalassemiatdtasystematicreview AT mousaalhiyari extramedullaryhematopoiesisinpatientswithtransfusiondependentbthalassemiatdtasystematicreview AT mohamedyassin extramedullaryhematopoiesisinpatientswithtransfusiondependentbthalassemiatdtasystematicreview AT hassanchoudry extramedullaryhematopoiesisinpatientswithtransfusiondependentbthalassemiatdtasystematicreview AT ashrafsoliman extramedullaryhematopoiesisinpatientswithtransfusiondependentbthalassemiatdtasystematicreview AT vincenzodesanctis extramedullaryhematopoiesisinpatientswithtransfusiondependentbthalassemiatdtasystematicreview
_version_	1718440557863239680

EXTRAMEDULLARY HEMATOPOIESIS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (TDT): A SYSTEMATIC REVIEW

Ejemplares similares